6,246 Shares of Johnson & Johnson $JNJ Acquired by Bernicke Wealth Management Ltd.

Bernicke Wealth Management Ltd. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 6,246 shares of the company’s stock, valued at approximately $1,654,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Outlook Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $28,000. Matrix Trust Co lifted its position in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after acquiring an additional 54 shares in the last quarter. Navigoe LLC lifted its position in Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after acquiring an additional 55 shares in the last quarter. Montgomery Financial Services LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $43,000. Finally, Hanseatic Management Services Inc. purchased a new position in Johnson & Johnson in the 3rd quarter worth approximately $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are a few of the latest headlines about JNJ:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet

Analysts Set New Price Targets

Several brokerages have issued reports on JNJ. Royal Bank Of Canada lowered their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 29th. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Argus set a $300.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Finally, Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Insider Activity

In related news, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 61,669 shares of company stock worth $16,898,386. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 0.8%

NYSE:JNJ opened at $285.78 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a one year low of $193.55 and a one year high of $288.11. The business’s 50-day simple moving average is $266.97 and its 200 day simple moving average is $249.85. The stock has a market cap of $687.95 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 2.80 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the prior year, the business posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.